Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Alopecia areata (AA) is a common autoimmune disorder causing patchy hair loss. Epidemiological observations and molecular studies collectively suggest an underrecognized interplay between AA and cardiovascular disease (CVD). However, the relationship between them remains controversial and requires further investigation.
Objective: To evaluate the association between AA and CVD through a meta-analysis of combinable results.
Methods: We systematically searched four databases (MEDLINE, Embase, Web of Science, and Cochrane Library) for relevant studies from inception to December 6, 2024. Studies included in the analysis were cohort or case-control studies that focused on the relationship between AA and CVD. Two independent reviewers extracted the data. The study quality was evaluated using the Newcastle-Ottawa Scale. A random-effects model was used for meta-analysis to calculate the odds ratio (OR) and 95% confidence intervals (CIs).
Results: Our search yielded five studies involving 238,270 AA patients from three countries. The meta-analysis revealed that AA patients had an increased OR (OR = 1.71; 95% CI: 1.0 to 2.92; < 0.01) for CVD outcomes compared to the control group. Subgroup analysis revealed a stronger risk in patients with alopecia totalis or alopecia universalis (OR = 3.80; 95% CI: 1.65 to 8.73; < 0.01). Associations were not observed between patch-type AA and CVD, nor between AA and ischemic stroke or myocardial infarction.
Conclusions: This meta-analysis suggests that AA patients, especially those with alopecia totalis or alopecia universalis, may have an elevated risk of developing CVD. Given the shared immunological mechanisms, systemic inflammation in AA may contribute to the development of atherosclerosis and increased cardiovascular risk. Further studies are needed to validate these findings and clarify the underlying mechanisms.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12367736 | PMC |
| http://dx.doi.org/10.3389/fimmu.2025.1643709 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Upadacitinib Therapy in Adolescent Severe Alopecia Areata: A Case Series and Narrative Review.
Clin Cosmet Investig Dermatol
September 2025
Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, 100730, People's Rep
Purpose: Alopecia areata (AA) is a common, immune-mediated, non-scarring form of hair loss. Janus kinase inhibitors provide considerable insight into the treatment of severe AA. However, the efficacy and safety of upadacitinib treatment of adolescents and pediatric patients with severe AA is unclear, especially in those without concomitant atopic diseases.
View Article and Find Full Text PDFCoexistence of bullous pemphigoid, intrahepatic cholangiocarcinoma, and alopecia areata: a case report of multifactorial autoimmunity in a surgical context.
Front Immunol
September 2025
Department of Dermatology, The National Center for the Integration of Traditional Chinese and Western Medicine, China-Japan Friendship Hospital, Beijing, China.
Background: Bullous Pemphigoid (BP) is caused by a predominantly Th2-mediated attack on the basement membrane by the production of anti-BP180 and anti-BP230 antibodies. Malignant tumors can exacerbate immune disorders through a variety of potential pathways, including pro-inflammatory responses in the tumor microenvironment, cross-immune responses induced by tumor-associated antigens, and the lifting of immunosuppressive states and activation of underlying autoimmune responses after surgery. Alopecia Areata (AA) is an autoimmune disease caused by T-lymphocyte-mediated destruction of the immune privilege of the hair follicle, specifically involving the immune axes of Th1, Th2 and Th17.
View Article and Find Full Text PDFAsynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.
Telemed Rep
August 2025
Medical Center Department of Dermatology, University of Pittsburgh, Wexford, Pennsylvania, USA.
Background: Non-scarring alopecia, including androgenetic alopecia (AGA), alopecia areata (AA), telogen effluvium (TE), and traction alopecia (TA), significantly impacts psychosocial well-being. Access to specialized dermatologic care for these conditions is often limited, particularly in underserved populations. Asynchronous teledermatology has emerged as a potential solution to extend care to these groups.
View Article and Find Full Text PDFDuration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.
J Dermatolog Treat
December 2025
Department of Dermatology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Objectives: Baricitinib showed efficacy for alopecia areata (AA) in clinical trials, with real-world data supporting its short-term effectiveness. However, long-term data are limited. We assessed the effectiveness and safety of baricitinib in AA patients over one year and explored predictive factors.
View Article and Find Full Text PDFPost-COVID-19 Alopecia Universalis: Autoimmune Hair Loss and the Challenge of Relapse Management.
J Drugs Dermatol
September 2025
Background: Alopecia universalis (AU) is the most severe form of alopecia areata (AA), characterized by complete scalp and body hair loss. While post-COVID-19 hair loss is often attributed to telogen effluvium (TE), emerging evidence suggests that COVID-19 may also trigger AU through immune dysregulation, particularly via interferon-gamma (IFN-γ)-mediated inflammation. The chronic and relapsing nature of AU raises challenges in long-term disease management, particularly regarding treatment duration and relapse prevention.
View Article and Find Full Text PDF